keyword
MENU ▼
Read by QxMD icon Read
search

Hodgkin NOT non-hodgkin*

keyword
https://www.readbyqxmd.com/read/28230270/a-phase-2-study-of-lenalidomide-rituximab-cyclophosphamide-and-dexamethasone-lr-cd-for-untreated-low-grade-non-hodgkin-lymphoma-requiring-therapy
#1
Allison Rosenthal, Amylou C Dueck, Stephen Ansell, Katherine Gano, Christopher Conley, Grzegorz S Nowakowski, John Camoriano, Jose F Leis, Joseph R Mikhael, A Keith Stewart, David Inwards, David Dingli, Shaji Kumar, Pierre Noel, Morie Gertz, Luis Porrata, Stephen Russell, Joseph Colgan, Rafael Fonseca, Thomas M Habermann, Prashant Kapoor, Francis Buadi, Nelson Leung, Rodger Tiedemann, Thomas E Witzig, Craig Reeder
Patients with indolent NHL have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in relapsed lymphoma. This trial was conducted to assess feasibility, efficacy and safety of adding lenalidomide to rituximab, cyclophosphamide, and dexamethasone (LR-CD) in untreated indolent NHL patients requiring therapy. This was a single institution phase II trial. Treatment consisted of IV rituximab 375mg/m(2) day 1, oral lenalidomide 20mg days 1-21, cyclophosphamide 250mg/m(2) days 1, 8, 15, and dexamethasone 40mg days 1, 8, 15, 22, of a 28-day cycle...
February 23, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28220934/advanced-stage-nodular-lymphocyte-predominant-hodgkin-lymphoma-in-children-and-adolescents-clinical-characteristics-and-treatment-outcome-a-report-from-the-sfce-cclg-groups
#2
Ananth G Shankar, Gaelle Roques, Amy A Kirkwood, Anne Lambilliotte, Katja Freund, Thierry Leblanc, Janis Hayward, Samuel Abbou, Alan D Ramsay, Claudine Schmitt, Stephanie Gorde-Grosjean, Hélène Pacquement, Stephanie Haouy, Sabah Boudjemaa, Nathalie Aladjidi, Georgina W Hall, Judith Landman-Parker
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) is extremely rare in children and as a consequence, optimal treatment for this group of patients has not been established. Here we retrospectively evaluated the treatments and treatment outcomes of 41 of our patients from the UK and France with advanced stage nLPHL. Most patients received chemotherapy, some with the addition of the anti CD20 antibody rituximab or radiotherapy. Chemotherapy regimens were diverse and followed either classical Hodgkin lymphoma or B non-Hodgkin lymphoma protocols...
February 21, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28214146/impact-of-anti-tnf-therapy-on-nk-cells-function-and-on-immunosurveillance-against-b-cell-lymphomas
#3
Gaetane Nocturne, Saida Boudaoud, Bineta Ly, Juliette Pascaud, Audrey Paoletti, Xavier Mariette
OBJECTIVES: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce an additional risk. Since, NK cells have been recently shown to participate to anti-lymphoma immunosurveillance, we aimed to assess if anti-TNF might impact their anti-lymphoma activity. METHODS: NK cells have been assessed ex vivo in patients with RA treated with methotrexate (MTX) with or without anti-TNF...
February 14, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28214006/-conduct-of-epidemiologic-studies-in-french-cancer-survivors-methods-difficulties-encountered-and-solutions-provided-lessons-learned-from-the-simonal-study-on-long-term-toxicities-after-non-hodgkin-lymphoma-treatment
#4
Sabine Anthony, Pierre Hebel, André Garrel, Vanina Oliveri, Catherine Thieblemont, Vincent Ribrag, Hervé Tilly, Corinne Haioun, René-Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, Richard Delarue, Loic Ysebaert, Catherine Sebban, Florence Broussais, Gandhi Damaj, Virginie Nerich, Jean-Philippe Jais, Gilles Salles, Michel Henry-Amar, Nicolas Mounier
INTRODUCTION: Since the introduction of targeted therapies, specific lymphoma mortality has decreased. Possible long-term toxicities, however, are not known yet. This article describes the implementation of the SIMONAL study that investigates the hypothesis of an overconsumption of care after lymphoma treatment with a 10-year follow-up. METHODS: After the mandatory regulatory steps (CCTIRS and CNIL) the vital status and address of 5247 patients treated in 131 French centers were retrieved using a secure web portal, in order to send a quality of life after lymphoma questionnaire...
February 14, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28212666/classical-hodgkin-lymphoma-masquerading-as-chronic-recurrent-multifocal-osteomyelitis-a-case-report
#5
Michael Pham, Steven Ressler, Allison Rosenthal, Katalin Kelemen
BACKGROUND: Hodgkin lymphoma is a hematologic malignancy usually confined to lymphatic structures and commonly associated with constitutional symptoms. Bony involvement and musculoskeletal symptoms are uncommon and typically seen in advanced disease. In this case, we report an unusual presentation of classical Hodgkin lymphoma and highlight diagnostic challenges leading to the misdiagnosis and treatment as chronic recurrent multifocal osteomyelitis. CASE PRESENTATION: A 38-year-old white man presented with lower extremity musculoskeletal pain...
February 18, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28209658/relevance-of-id3-tcf3-ccnd3-pathway-mutations-in-pediatric-aggressive-b-cell-lymphoma-treated-according-to-the-nhl-bfm-protocols
#6
Marius Rohde, Bettina R Bonn, Martin Zimmermann, Jonas Lange, Anja Möricke, Wolfram Klapper, Ilske Oschlies, Monika Szczepanowski, Inga Nagel, Martin Schrappe, Markus Loeffler, Reiner Siebert, Alfred Reiter, Birgit Burkhardt
Mature B-cell Non-Hodgkin lymphoma is the most common subtype of Non-Hodgkin lymphoma in childhood and adolescence. B-cell Non-Hodgkin lymphoma are further classified into histological subtypes, with Burkitt lymphoma and Diffuse large B-cell lymphoma being the most common subgroups in pediatric patients. Translocations involving the MYC oncogene are known as relevant but not sufficient hit for Burkitt lymphoma pathogenesis. Recently published large-scale next-generation sequencing studies unveiled sets of additional recurrently mutated genes in samples of pediatric and adult B-cell Non-Hodgkin lymphoma patients...
February 16, 2017: Haematologica
https://www.readbyqxmd.com/read/28197722/reallocating-time-to-sleep-sedentary-and-active-behaviours-in-non-hodgkin-lymphoma-survivors-associations-with-patient-reported-outcomes
#7
Jeff K Vallance, Matthew P Buman, Brigid M Lynch, Terry Boyle
The purpose of this study was to examine potential effects of reallocating time between sleep, sedentary and active behaviours on fatigue symptoms and quality of life in a sample of non-Hodgkin lymphoma survivors. Non-Hodgkin lymphoma survivors identified from the Western Australian Cancer Registry (N = 149) (response rate = 36%; median age = 64 years) wore an Actigraph® GT3X+ accelerometer for 7 days and completed the Fatigue Scale, the Functional Assessment of Cancer Therapy-General and the Pittsburgh Sleep Quality Index...
February 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28196364/technetium-99m-or-cy7-labeled-rituximab-as-an-imaging-agent-for-non-hodgkin-lymphoma
#8
Ximena Camacho, Camila Longo Machado, María Fernanda García, Juan Pablo Gambini, Agustina Banchero, Marcelo Fernández, Natalia Oddone, Daniela Bertolini Zanatta, Carolina Rosal, Carlos Alberto Buchpiguel, Roger Chammas, Eloisa Riva, Pablo Cabral
INTRODUCTION: Rituximab was the first monoclonal antibody approved for the treatment of B-cell non-Hodgkin lymphoma (NHL) expressing CD20 antigen. This antibody has also the potential to be used as a specific fluorescent and radiolabel agent for targeting NHL. OBJECTIVE: To radiolabel rituximab with technetium-99m (99mTc) or Cy7 and evaluate both probes as potential imaging agents for NHL. METHODS: Rituximab was derivatized with the trifluoroacetyl hydrazino protected form of succinimidyl ester of HYNIC and radiolabeled with 99mTc...
February 15, 2017: Oncology
https://www.readbyqxmd.com/read/28196110/ethnic-variation-in-medical-and-lifestyle-risk-factors-for-b-cell-non-hodgkin-lymphoma-a-case-control-study-among-israelis-and-palestinians
#9
Geffen Kleinstern, Rania Abu Seir, Riki Perlman, Areej Khatib, Ziad Abdeen, Husein Elyan, Ronit Nirel, Gail Amir, Asad Ramlawi, Fouad Sabatin, Paolo Boffetta, Eldad J Dann, Meirav Kedmi, Martin Ellis, Arnon Nagler, Dina Ben Yehuda, Ora Paltiel
BACKGROUND: Risk factors for B-cell non-Hodgkin lymphoma (B-NHL) have not been assessed among Palestinian Arabs (PA) and Israeli Jews (IJ). METHODS: In a case-control study we investigated self-reported medical and lifestyle exposures, reporting odds ratios (ORs) and 95% confidence intervals [CIs], by ethnicity, for overall B-NHL and subtypes. RESULTS: We recruited 823 cases and 808 healthy controls. Among 307 PA/516 IJ B-NHL cases (mean age at diagnosis = 51 [±17] versus 60 [±15] years, respectively) subtype distributions differed, with diffuse large B-cell lymphoma (DLBCL) being prominent among PA (71%) compared to IJ (41%); follicular lymphoma (FL), was observed in 14% versus 28%, and marginal zone lymphoma, in 2% versus 14%, respectively...
2017: PloS One
https://www.readbyqxmd.com/read/28194276/a-case-report-of-concurrent-embryonal-rhabdomyosarcoma-and-diffuse-large-b-cell-lymphoma-in-an-adult-without-identifiable-cancer-predisposition
#10
M D Mathias, M V Ortiz, H Magnan, S R Ambati, E K Slotkin, A J Chou, M F Walsh, K Offit, C Moskowitz, A Kentsis, L H Wexler
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Rhabdomyosarcoma, the most common soft tissue sarcoma of childhood. makes up less than 1% of solid malignancies in adults with around 400 new cases each year in the United States. They have not previously been reported concurrently. CASE PRESENTATION: A 37 year old woman presented with painful enlarging leg mass. Biopsy of the mass was consistent with embryonal rhabdomyosarcoma...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28193996/a-case-report-of-primary-nasal-natural-killer-nk-t-cell-lymphoma-in-an-african-american-patient-presenting-with-hemophagocytic-syndrome
#11
Bowei Tan, Cherif Abdelmalek, James E O'Donnell, Thomas Toltaku, Rashid Chaudhry, Jen C Wang, Vladimir Gotlieb
BACKGROUND Extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL) is generally an aggressive and rare non-Hodgkin lymphoma. It is most common in East Asians, Native Americans, and South Americans, but is rarely reported in blacks. CASE REPORT A 55-year-old African American male born in Grenada presented with a left nostril mass with facial swelling and biopsy subsequently confirmed a diagnosis of extranodal NK/T-cell lymphoma, nasal type (ENKTCL). Immunochemistry was positive for CD2, cytoplasmic CD3, CD7, CD 43, CD 56, granzyme B, and TIA-1...
February 14, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28184983/sexual-problems-in-male-vs-female-non-hodgkin-lymphoma-survivors-prevalence-correlates-and-associations-with-health-related-quality-of-life
#12
Im-Ryung Kim, Soo Hyun Kim, Oh Nam Ok, So Hee Kim, Suyeon Lee, Eunju Choi, Seok Jin Kim, Dok Hyun Yoon, Moon Hee Lee
The objective of this study was to examine the prevalence and factors associated with sexual problems and their relationship to health-related quality of life (HRQOL) in male and female non-Hodgkin lymphoma (NHL) survivors. In this cross-sectional study, 738 NHL survivors (425 men and 313 women; mean time since diagnosis, 6.2 years) in South Korea completed the six-item instrument of adult sexual behavior used by the National Health and Social Life Survey in the United States. HRQOL was measured by two subscales of the EORTC QLQ-C30...
February 9, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28182089/a-rare-case-of-signet-ring-cell-lymphoma-diagnosis-aided-by-immunofluorescent-staining
#13
Charusheela R Gore, N K Panicker, Harsh Kumar, Archana Buch, S S Chandanwale
Signet ring cell lymphomas are the proliferations of malignant lymphoid cells containing cytoplasmic vacuoles or globules which displace the nuclei, imparting it a signet ring appearance. This rare tumor is a variant of non-Hodgkin lymphoma. Signet ring appearance is due to cytoplasmic accumulation of immunoglobulin or vacuoles derived from multivesicular bodies. These cells, particularly with cytoplasmic vacuoles, may be mistaken for adenocarcinoma cells. We are presenting one such case where immunofluorescence helped us to demonstrate the immunoglobulins on fine needle aspiration smears...
January 2017: Journal of Cytology
https://www.readbyqxmd.com/read/28178905/adult-t-cell-leukemia-lymphoma-in-south-and-central-america-and-the-caribbean-systematic-search-and-review
#14
Pedro D Oliveira, Rebeca F de Carvalho, Achiléa L Bittencourt
Adult T-cell leukemia/lymphoma (ATL) is caused by the human T-cell lymphotropic virus type 1 (HTLV-1) which is endemic in countries of Caribbean and Central and South America. We performed a systematic search and review to identify publications on ATL in these countries to verify if this disease was getting recognition in these regions as well as the characteristics of the observed cases. The median age of 49.4 years was lower than that referred to in Japan. According to our findings in most Brazilian states and in some other countries, ATL is not being recognized and should be strongly considered in the differential diagnosis of T-cell leukemias/lymphomas...
March 2017: International Journal of STD & AIDS
https://www.readbyqxmd.com/read/28177920/predictable-biomarkers-of-developing-lymphoma-in-patients-with-sj%C3%A3-gren-syndrome-a-nationwide-population-based-cohort-study
#15
Yu-Hsiang Chiu, Chi-Hsiang Chung, Kuen-Tze Lin, Chin-Sheng Lin, Jia-Hong Chen, Hsiang-Cheng Chen, Ren-Yeong Huang, Chi-Tsung Wu, Feng-Cheng Liu, Wu-Chien Chien
Sjögren syndrome (SS) is commonly known to be correlated with lymphoma. This study included 16,396 individuals in the SS cohort and 65,584 individuals in the non-SS cohort, all of whom were enrolled in the Taiwan National Health Insurance database between 2000 and 2010. We evaluated the risk factors of non-Hodgkin's lymphoma (NHL) in the primary SS cohort by applying a Cox multivariable proportional-hazards model. We increased the correlation of patients with SS and NHL, with an adjusted HR of 4.314 (95% CI 2...
February 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28177577/lymph-node-stiffness-mimicking-hydrogels-regulate-human-b-cell-lymphoma-growth-and-cell-surface-receptor-expression-in-a-molecular-subtype-specific-manner
#16
Fnu Apoorva, Ye F Tian, Timothy M Pierpont, David M Bassen, Leandro Cerchietti, Jonathan T Butcher, Robert S Weiss, Ankur Singh
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma, with multiple molecular subtypes. The activated B cell-like DLBCL subtype accounts for roughly one-third of all the cases and has an inferior prognosis. There is a need to develop better class of therapeutics that could target molecular pathways in resistant DLBCLs; however this requires DLBCLs to be studied in representative tumor microenvironments. The pathogenesis and progression of lymphoma has been mostly studied from the point of view of genetic alterations and intracellular pathway dysregulation...
February 8, 2017: Journal of Biomedical Materials Research. Part A
https://www.readbyqxmd.com/read/28157210/modulation-of-macrophage-antitumor-potential-by-apoptotic-lymphoma-cells
#17
Jorine J L P Voss, Catriona A Ford, Sofia Petrova, Lynsey Melville, Margaret Paterson, John D Pound, Pam Holland, Bruno Giotti, Tom C Freeman, Christopher D Gregory
In aggressive non-Hodgkin's lymphoma (NHL), constitutive apoptosis of a proportion of the tumor cell population can promote net tumor growth. This is associated with the accumulation of tumor-associated macrophages (TAMs) that clear apoptotic cells and exhibit pro-oncogenic transcriptional activation profiles characteristic of reparatory, anti-inflammatory and angiogenic programs. Here we consider further the activation status of these TAMs. We compare their transcriptomic profile with that of a range of other macrophage types from various tissues noting especially their expression of classically activated (IFN-γ and LPS) gene clusters - typically antitumor - in addition to their previously described protumor phenotype...
February 3, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28156591/symptom-burdens-and-coping-strategies-in-adolescent-and-young-adult-aya-cancer-survivors-with-hematologic-malignancies
#18
Lori S Muffly, Joseline X Gomez, Kate Breitenbach, Jennifer Lynn McNeer, Wendy Stock, Christopher Daugherty
: 256 Background: Prior research reveals that AYA survivors face significant short-term and long-term physical and psychological symptom burdens (SB) as a result of disease and treatment. Yet, the prevalence of SB and their effect on AYA coping in hematologic survivors has not been described. METHODS: AYA patients (15-40 years at diagnosis) of acute leukemia, aggressive non-Hodgkin lymphoma, and Hodgkin lymphoma undergoing curative intent therapy (on-treatment cohort) or 2 year completion of therapy and in remission (early survivor cohort) completed following measures: depression (CES-D), state anxiety (STAI-S), PTSD (PCL-C), HRQOL (FACIT-G), Coping (Brief COPE)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156055/combination-of-rituximab-and-nonpegylated-liposomal-doxorubicin-r-npld-as-front-line-therapy-for-aggressive-non-hodgkin-lymphoma-nhl-in-patients-80%C3%A2-years-of-age-or-older-a-single-center-retrospective-study
#19
Giuseppina Ricciuti, Erica Finolezzi, Stefania Luciani, Elena Ranucci, Massimo Federico, Marta Di Nicola, Isaia Antonio Luca Zecca, Francesco Angrilli
The incidence of non-Hodgkin lymphoma in patients 80 years of age or older is 50 times higher than in 20- to 24-year-olds. Very elderly patients are often not treated with standard immunochemotherapy because of poor performance status, comorbidities, and toxicity concerns. We retrospectively analyzed data for 29 patients diagnosed with diffuse large B-cell lymphoma or grade 3B follicular lymphoma and treated with rituximab in combination with nonpegylated liposomal doxorubicin between January 2010 and August 2015...
February 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28154512/interleukin-10-polymorphisms-in-association-with-prognosis-in-patients-with-b-cell-lymphoma-treated-by-r-chop
#20
Min Kyeong Kim, Kyong-Ah Yoon, Eun Young Park, Jungnam Joo, Eun Young Lee, Hyeon-Seok Eom, Sun-Young Kong
Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis...
December 2016: Genomics & Informatics
keyword
keyword
28289
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"